



www.genfit.com

GENFIT: CAPITAL INCREASE OF €500 K RESERVED TO AN HISTORICAL SHAREHOLDER

Lille (France), Cambridge (Massachusetts, United States), July 3rd, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces a capital increase of a gross amount of €500,000.40 (issue premium included), reserved to one of its historical shareholders.

The operation was performed following the decisions of the Management Board of June 28th and 29th 2012, taking into account the volume-weighted average share price during the five consecutive trading days preceding the operation, and according to the delegations granted to the Management Board by the Nineteenth and Twentieth Resolutions of the Extraordinary General Meeting of Shareholders held on June 26, 2012. The operation will result in the issue of 416,667 new shares immediately assimilated with existing shares. The number of shares that make up the capital will thus increase to 15,085,665.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr